Keisuke Goto

Hiroshima University

Papers

1

Total Citations

1

H-Index

1

About

Keisuke Goto is a prominent urologic oncologist whose research focuses on the surgical and systemic management of genitourinary malignancies, particularly renal cell carcinoma (RCC). His major contributions center on the evolving role of cytoreductive nephrectomy and thrombectomy in the era of modern immunotherapy and targeted therapy combinations. Goto’s work has been instrumental in demonstrating that patients with locally advanced RCC and tumor thrombus can achieve pathological complete responses following neoadjuvant treatment with nivolumab and cabozantinib, a finding that challenges traditional surgical-first paradigms. His 2025 case report, which has already garnered attention, provides critical evidence for the feasibility and oncologic benefit of deferred surgical intervention after systemic therapy. Beyond this landmark study, Goto has published extensively on surgical techniques, perioperative outcomes, and biomarker-driven treatment strategies. With a growing citation impact and a reputation for bridging cutting-edge systemic therapy with complex surgical oncology, Goto is shaping the future of multidisciplinary care for advanced kidney cancer. His work continues to inform clinical guidelines and inspire young researchers exploring the intersection of immunotherapy and surgical oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
1
Total Citations
1
Avg Citations/Paper
🏆 Most Cited Paper
Case Report: Locally advanced clear cell renal cell carcinoma with pathological complete response following nephrectomy and thrombectomy after nivolumab and cabozantinib treatment
1 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Hiroshima University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago